UNSPSC 51284907: Phenazopyridine/sulfamethizole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM650. This VA Drug Class (AM650) classifies this compound as belonging to the group SULFONAMIDE/RELATED ANTIMICROBIALS.

UNSPSC 51284907 Phenazopyridine/sulfamethizole is a Commodity code for urinary analgesic and antibiotic combination medications, but recent state and local procurement activity under this code shows minimal direct relevance. The three most recent opportunities posted under or near this code are dominated by broader health supply procurements: a Seminole County, Florida IFB for naloxone and drug deactivation systems (posted June 30, 2026); a City of Tampa IFB for medical and first aid supplies serving the Fire Department Rescue Division, with an estimated value of $700,000 (posted March 25, 2026); a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer pharmacy prescription programs (posted April 3, 2026); and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products with distribution across multiple state and local facilities (posted January 20, 2026). None of these solicitations explicitly target phenazopyridine/sulfamethizole compounds. The issuing bodies span county health departments, municipal fire services, state HHS agencies, and cooperative purchasing vehicles serving multiple jurisdictions.

Recent activity under this code reflects procurement from Florida, Texas, and Minnesota, along with Oregon participation in the MMCAP cooperative. The mismatch between the code's nominal scope—a specific pharmaceutical combination—and the actual procurement records suggests this code receives infrequent or misapplied tagging in state and local systems. Buyers pursuing pharmaceutical supply contracts with state and local governments typically encounter broader RFPs covering multi-source generics and OTC products through established wholesalers or cooperative purchasing alliances rather than single-compound solicitations. The MMCAP RFP (due March 26, 2026) and the Texas HHS RFI represent the most active market signals; both prioritize price competitiveness, regulatory compliance (cGMP, DSCSA, FDA), and wholesale distribution channel relationships. The Tampa and Seminole County opportunities demonstrate municipal and county health department procurement through sealed-bid processes with firm pricing and expedited delivery requirements, though neither directly solicits phenazopyridine/sulfamethizole products.